Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients

Objectives To determine the effect of etravirine on the pharmacokinetics of darunavir/cobicistat and vice versa. Safety and tolerability of this combination were also evaluated. Methods Open-label, fixed-sequence trial in two cohorts of HIV-infected patients on therapy with darunavir/cobicistat 800/150 mg once daily (DRV cohort; n = 15) or etravirine 400 mg once daily (ETR cohort; n = 15). Etravirine or darunavir/cobicistat were added on days 1-14 and 1-7 in participants in the DRV or ETR cohort, respectively. Full pharmacokinetic profiles were obtained on days 0 and 14 in the DRV cohort, and on days 0 and 7 in the ETR cohort. Darunavir, cobicistat and etravirine pharmacokinetic parameters [AUC0-24, Cmax and trough concentrations in plasma (C24)] were calculated for each individual by non-compartmental analysis and were compared using linear mixed-effects models. Adverse events and HIV-1 RNA in plasma were monitored. Results Etravirine co-administration decreased cobicistat AUC0-24, Cmax and C24 by 30%, 14% and 66%, respectively. Although darunavir AUC0-24 and Cmax were unchanged by etravirine, darunavir C24 was 56% lower for darunavir/cobicistat co-administered with etravirine relative to darunavir/cobicistat alone. Etravirine pharmacokinetics were unchanged by darunavir/cobicistat. Treatments were well tolerated, and HIV-1 RNA remained undetectable in all participants. Conclusions Although etravirine pharmacokinetics was unchanged by darunavir/cobicistat, there was a significant decrease in cobicistat exposure and in darunavir C24 when darunavir/cobicistat was co-administered with etravirine. Boosting darunavir with ritonavir instead of with cobicistat may be preferred if darunavir is to be combined with etravirine in clinical practice.

[1]  E. Acosta,et al.  Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults. , 2016, Journal of the Pediatric Infectious Diseases Society.

[2]  R. Asensi-Díez,et al.  [Dual therapy as an alternative treatment in HIV pretreated patients: experience in a tertiary hospital]. , 2016, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[3]  L. Yunquera-Romero,et al.  Biterapia como alternativa de tratamiento en los pacientes VIH pretratados: experiencia en un hospital de tercer nivel , 2016 .

[4]  N. Hentig.  Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy. , 2015 .

[5]  M. Ramgopal,et al.  The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single‐arm, open‐label study of etravirine and darunavir/ritonavir as dual therapy in HIV‐1‐infected early treatment‐experienced subjects , 2015, HIV medicine.

[6]  A. Curran,et al.  Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat. , 2015, AIDS reviews.

[7]  A. d’Arminio Monforte,et al.  Efficacy and Safety of Darunavir/Ritonavir Plus Etravirine Dual Regimen in Antiretroviral Therapy–Experienced Patients: A Multicenter Clinical Experience , 2014, HIV clinical trials.

[8]  V. Moreno,et al.  Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients , 2014, Journal of the International AIDS Society.

[9]  Sarah B. Laskey,et al.  Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.

[10]  A. Stolbach,et al.  A Review of the Toxicity of HIV Medications , 2013, Journal of Medical Toxicology.

[11]  C. Orkin,et al.  Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV‐1‐infected treatment‐naïve patients in the ARTEMIS trial , 2013, HIV medicine.

[12]  Namandjé N. Bumpus,et al.  Biotransformation of the Antiretroviral Drug Etravirine: Metabolite Identification, Reaction Phenotyping, and Characterization of Autoinduction of Cytochrome P450-Dependent Metabolism , 2012, Drug Metabolism and Disposition.

[13]  B. Gazzard,et al.  Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results , 2011, AIDS.

[14]  R. Haubrich,et al.  Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials , 2010, Antiviral therapy.

[15]  P. Ruane,et al.  Pharmacokinetics of once-daily Etravirine without and with Once-daily Darunavir/ritonavir in Antiretroviral-Naive HIV type-1-Infected Adults , 2010, Antiviral therapy.

[16]  Yujin Wang,et al.  Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer. , 2010, ACS medicinal chemistry letters.

[17]  P. German,et al.  Pharmacokinetics and Pharmacodynamics of GS‐9350: A Novel Pharmacokinetic Enhancer Without Anti‐HIV Activity , 2010, Clinical pharmacology and therapeutics.

[18]  M. Peeters,et al.  Pharmacokinetics of Darunavir/Ritonavir and TMC125 alone and Coadministered in HIV-Negative Volunteers , 2007, Antiviral therapy.

[19]  R. Haubrich,et al.  Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials , 2007, The Lancet.

[20]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[21]  Dirk Jochmans,et al.  TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates , 2005, Antimicrobial Agents and Chemotherapy.

[22]  R. Aarnoutse,et al.  Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. , 2003, Journal of acquired immune deficiency syndromes.